Hospital-based multidisciplinary lung cancer care in Australia: a survey of the landscape in 2021

Brims, FJH; Kumarasamy, C; Nash, J; Leong, TL; Stone, E; Marshall, HM

Author(s): Brims, FJH; Kumarasamy, C; Nash, J; Leong, TL; Stone, E; Marshall, HM;
Details: Publication Year 2022-01,Volume 9,Issue #1,Page e001157
Journal Title: BMJ Open Respiratory Research
Abstract: INTRODUCTION: Lung cancer is the leading cause of cancer death in Australia and has the highest cancer burden. Numerous reports describe variations in lung cancer care and outcomes across Australia. There are no data assessing compliance with treatment guidelines and little is known about lung cancer multidisciplinary team (MDT) infrastructure around Australia. METHODS: Clinicians from institutions treating lung cancer were invited to complete an online survey regarding the local infrastructure for lung cancer care and contemporary issues affecting lung cancer. RESULTS: Responses from 79 separate institutions were obtained representing 72% of all known institutions treating lung cancer in Australia. Most (93.6%) held a regular MDT meeting although recommended core membership was only achieved for 42/73 (57.5%) sites. There was no thoracic surgery representation in 17/73 (23.3%) of MDTs and surgery was less represented in regional and low case volume centres. Specialist nurses were present in just 37/79 (46.8%) of all sites. Access to diagnostic and treatment facilities was limited for some institutions. IT infrastructure was variable and most sites (69%) do not perform regular audits against guidelines. The COVID-19 pandemic has driven most sites to incorporate virtual MDT meetings, with variable impact around the country. Clinician support for a national data-driven approach to improving lung cancer care was unanimous. DISCUSSION: This survey demonstrates variations in infrastructure support, provision and membership of lung cancer MDTs, in particular thoracic surgery and specialist lung cancer nurses. This heterogeneity may contribute to some of the well-documented variations in lung cancer outcomes in Australia.
Keywords: Australia/epidemiology; *covid-19; Hospitals; Humans; *Lung Neoplasms/diagnosis/epidemiology/therapy; Pandemics; Patient Care Team; SARS-CoV-2; *lung cancer
Research Division(s): Personalised Oncology
PubMed ID: 35039312
Publisher's Version: https://doi.org/10.1136/bmjresp-2021-001157
Open Access at Publisher's Site: https://doi.org/10.1136/bmjresp-2021-00115
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2022-02-18 11:36:33

Last Modified: 2022-02-18 01:11:54